Boston Scientific has completed enrollment in its Maps clinical trial, which is studying the coiling of intracranial aneurysms. This prospective, randomized trial commenced enrollment in 2007 and has
BioVectra has signed agreements with Sandoz, whereunder Sandoz will commercialise and market the Abbreviated New Drug Application (ANDA) for Docetaxel for injection, the generic version of Taxotere developed
Formatech has selected the next candidate as ViroMed’s VM206 therapeutic cancer vaccine for its Fillanthropy Program. Under the Fillanthropy Program, Formatech will donate the services required to aseptically
DMV-Fonterra Excipients, the 50/50 joint venture between Royal FrieslandCampina and Fonterra for pharmaceutical excipients, has reported to buy the activities of FrieslandCampina Domo in pharmaceutical lactose as per
China Aoxing Pharmaceutical (China Aoxing) has completed Phase II clinical study for oral TJSL capsules, an investigational drug to treat primary dysmenorrhea (PD) , or menstrual pain, in
Excaliard Pharmaceuticals (Excaliard) has initiated three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and
Intellikine has initiated a Phase I clinical trial for its targeted anticancer drug INK128, an orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components
Zydus Cadila has received approval from the Drug Controller General of India (DCGI) to conduct clinical trials for the H1N1 (swine flu) vaccine. The egg based, inactivated vaccine
Evolva has signed an agreement with Roche, to create compounds with activity on targets in oncology and anti-infectives using Evolva’s technology platform. Roche is expected to pay Evolva
Novartis intends to gain full ownership of Alcon by completing the April 2008 agreement with Nestle to acquire a 77% majority stake in eye care and subsequently entering
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.